Michel Lagarde
Known title: Executive Vice President & COOCIK: 0001518973
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Vertex Highlights Sickle Cell Gene Therapy and Hormone Disorder Expansion. Vertex Pharmaceuticals is advancing a gene therapy for sickle cell disease, which could broaden its treatment portfolio but faces access challenges. The company also signals a potential new growth area in hormone disorders, moving beyond cystic fibrosis. With earnings approaching, investors are watching how these developments affect the company’s outlook. The stock has risen above the market recently, reflecting positive sentiment.
Transaction History
| TMO | ▼ Sell | Tax Withholding | 837 | $436K | 2/28/2026 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 360 | $187K | 2/28/2026 | View on chart |
| TMO | ▲ Buy | Grant | 2,231 | $0 | 2/25/2026 | View on chart |
| TMO | ▼ Sell | Open Market | 22,046 | $12.4M | 12/4/2025 | View on chart |
| TMO | ▲ Buy | Option Exercise | 18,637 | $2.0M | 12/4/2025 | View on chart |
| TMO | ▲ Buy | Option Exercise | 22,046 | $2.9M | 12/4/2025 | View on chart |
| TMO | ▲ Buy | Option Exercise | 68,000 | $7.2M | 12/3/2025 | View on chart |
| TMO | ▼ Sell | Open Market | 29,479 | $17.2M | 12/3/2025 | View on chart |
| TMO | ▼ Sell | Open Market | 2,521 | $1.5M | 12/3/2025 | View on chart |
| TMO | ▲ Buy | Option Exercise | 36,000 | $3.8M | 12/2/2025 | View on chart |
| TMO | ▼ Sell | Open Market | 30,000 | $17.5M | 12/2/2025 | View on chart |
| TMO | ▲ Buy | Option Exercise | 4,638 | $1.2M | 11/13/2025 | View on chart |
| TMO | ▼ Sell | Open Market | 4,638 | $2.8M | 11/13/2025 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 262 | $128K | 8/28/2025 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 262 | $128K | 8/28/2025 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 275 | $135K | 8/28/2025 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 162 | $79K | 8/28/2025 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 433 | $229K | 2/28/2025 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 1,125 | $595K | 2/28/2025 | View on chart |
| TMO | ▲ Buy | Grant | 7,418 | $0 | 2/19/2025 | View on chart |
| TMO | ▲ Buy | Grant | 2,231 | $0 | 2/19/2025 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 262 | $161K | 8/28/2024 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 219 | $134K | 8/28/2024 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 165 | $101K | 8/28/2024 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 504 | $306K | 8/23/2024 | View on chart |
| TMO | ▼ Sell | Open Market | 20,000 | $11.8M | 5/14/2024 | View on chart |
| TMO | ▲ Buy | Option Exercise | 20,000 | $2.1M | 5/14/2024 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 1,013 | $579K | 2/28/2024 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 512 | $289K | 2/23/2024 | View on chart |
| TMO | ▲ Buy | Grant | 2,275 | $0 | 2/21/2024 | View on chart |
| VRTX | ▲ Buy | Grant | 1,132 | $0 | 10/5/2023 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 219 | $119K | 8/28/2023 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 132 | $72K | 8/28/2023 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 642 | $348K | 8/25/2023 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 504 | $275K | 8/23/2023 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 131 | $73K | 3/5/2023 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 1,019 | $552K | 2/28/2023 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 915 | $504K | 2/23/2023 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 981 | $540K | 2/23/2023 | View on chart |
| TMO | ▲ Buy | Grant | 6,323 | $0 | 2/22/2023 | View on chart |
| TMO | ▲ Buy | Grant | 1,809 | $0 | 2/22/2023 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 120 | $68K | 8/28/2022 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 566 | $319K | 8/26/2022 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 589 | $345K | 8/25/2022 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 385 | $221K | 8/23/2022 | View on chart |
| TMO | ▲ Buy | Option Exercise | 3,893 | $1.8M | 5/27/2022 | View on chart |
| TMO | ▲ Buy | Option Exercise | 9,137 | $2.8M | 5/27/2022 | View on chart |
| TMO | ▼ Sell | Open Market | 1,182 | $669K | 5/27/2022 | View on chart |
| TMO | ▼ Sell | Open Market | 3,117 | $1.8M | 5/27/2022 | View on chart |
| TMO | ▼ Sell | Open Market | 8,731 | $4.9M | 5/27/2022 | View on chart |
| TMO | ▲ Buy | Option Exercise | 6,049 | $1.3M | 5/26/2022 | View on chart |
| TMO | ▲ Buy | Option Exercise | 10,715 | $2.7M | 5/26/2022 | View on chart |
| TMO | ▼ Sell | Open Market | 7,083 | $3.8M | 5/26/2022 | View on chart |
| TMO | ▼ Sell | Open Market | 7,542 | $4.0M | 5/26/2022 | View on chart |
| TMO | ▼ Sell | Open Market | 2,139 | $1.1M | 5/26/2022 | View on chart |
| TMO | ▼ Sell | Open Market | 200 | $109K | 5/25/2022 | View on chart |
| TMO | ▲ Buy | Option Exercise | 1,851 | $390K | 5/25/2022 | View on chart |
| TMO | ▲ Buy | Option Exercise | 3,197 | $812K | 5/25/2022 | View on chart |
| TMO | ▼ Sell | Open Market | 1,125 | $608K | 5/25/2022 | View on chart |
| TMO | ▼ Sell | Open Market | 2,068 | $1.1M | 5/25/2022 | View on chart |
| TMO | ▼ Sell | Open Market | 826 | $448K | 5/25/2022 | View on chart |
| TMO | ▼ Sell | Open Market | 357 | $194K | 5/25/2022 | View on chart |
| TMO | ▼ Sell | Open Market | 472 | $257K | 5/25/2022 | View on chart |
| TMO | ▲ Buy | Option Exercise | 14,900 | $2.8M | 5/24/2022 | View on chart |
| TMO | ▼ Sell | Open Market | 542 | $295K | 5/24/2022 | View on chart |
| TMO | ▼ Sell | Open Market | 4,908 | $2.7M | 5/24/2022 | View on chart |
| TMO | ▼ Sell | Open Market | 3,783 | $2.1M | 5/24/2022 | View on chart |
| TMO | ▼ Sell | Open Market | 2,792 | $1.5M | 5/24/2022 | View on chart |
| TMO | ▲ Buy | Option Exercise | 2,250 | $662K | 5/24/2022 | View on chart |
| TMO | ▼ Sell | Open Market | 3,392 | $1.9M | 5/24/2022 | View on chart |
| TMO | ▼ Sell | Open Market | 1,033 | $564K | 5/24/2022 | View on chart |
| TMO | ▼ Sell | Open Market | 700 | $386K | 5/24/2022 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 120 | $66K | 3/5/2022 | View on chart |
| TMO | ▼ Sell | Open Market | 1,000 | $542K | 3/1/2022 | View on chart |
| TMO | ▼ Sell | Open Market | 5,100 | $2.8M | 3/1/2022 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 1,025 | $564K | 2/25/2022 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 899 | $475K | 2/23/2022 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 864 | $457K | 2/23/2022 | View on chart |
| TMO | ▲ Buy | Grant | 1,806 | $0 | 2/23/2022 | View on chart |
| TMO | ▲ Buy | Grant | 6,081 | $0 | 2/23/2022 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 293 | $161K | 8/27/2021 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 566 | $313K | 8/26/2021 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 491 | $269K | 8/25/2021 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 232 | $128K | 8/23/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Thermo Fisher Outperforms on Life Sciences Recovery
Thermo Fisher Scientific reported strong results driven by a recovery in the life sciences sector. Growth in academic and government spending is supporting demand for the company's products. Analysts note that increasing omics demand could further influence the stock's outlook.
Thermo Fisher Outperforms on Life Sciences Recovery. Thermo Fisher Scientific reported strong results driven by a recovery in the life sciences sector. Growth in academic and government spending is supporting demand for the company's products. Analysts note that increasing omics demand could further influence the stock's outlook.